Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951112 | 0.87 | RAB9A (0.77) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11119624 | 0.86 | RAB9A (0.62) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL2259491 | 0.86 | EGFR (0.62) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL1758718 | 0.85 | EGFR (0.66) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL9416888 | 0.84 | EGFR (0.47) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL11158107 | 0.84 | EGFR (0.69) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL4543722 | 0.84 | EGFR (0.64) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL9891521 | 0.84 | EGFR (0.64) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL9893035 | 0.83 | EGFR (0.51) | EGFRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL28467424 | 0.83 | EGFR (0.48) | EGFRNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119264133-A | Selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| EP-3473624-B1 | NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-05-11 | — | — | EP | disclosed |
| EP-3169671-B1 | 1-(5-(TERT.-BUTYL)ISOXAZOL-3-YL)-3-(4-((PHENYL)ETHYNYL)PHENYL)UREA DERIVATIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATING CANCER | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-2739143-B1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5- MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | FLYNN GARY A (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017206962-A1 | NOVEL INHIBITOR FOR FLT3 KINASE AND USES THEREOF | 合肥中科普瑞昇生物医药科技有限公司 | 2017-12-07 | — | — | WO | disclosed |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2484342-A1 | Hair resiliency / body improver and hair cosmetic | Shiseido Company, Limited (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | SHISEIDO COMPANY, LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
| WO-2009105509-A1 | AMINE AND ETHER COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
| EP-1911750-A1 | AGENT FOR IMPROVEMENT IN BOUNCE/BODY OF HAIR, AND HAIR COSMETIC | Shiseido Company, Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-4116671-A | HERBICIDES | SHIONOGI & CO., LTD. (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4111680-A | HERBICIDAL COMPOSITIONS CONTAINING 3-ISOXAZOLYLUREA DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4062861-A | HERBICIDE | SHIONOGI & CO., LTD. (JA) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | EGFR 4664/4885NPC1 377/4885RAB9A 3215/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | EGFR 4553/4885NPC1 414/4885RAB9A 2987/4885 |
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | MC1R, PNISR, HCRTR1 | EGFR 431/4885NPC1 4539/4885RAB9A 3630/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | EGFR 4872/4885NPC1 348/4885RAB9A 3477/4885 |
| US-20130184315-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, GPR52 | EGFR 640/4885NPC1 1089/4885RAB9A 2495/4885 |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | EGFR 896/4885NPC1 1779/4885RAB9A 2445/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | EGFR 970/4885NPC1 1904/4885RAB9A 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.